Literature DB >> 23650161

Determination of voriconazole serum concentration by bioassay, a valid method for therapeutic drug monitoring for clinical laboratories.

Emilio Cendejas-Bueno1, Manuel Cuenca-Estrella, Alicia Gomez-Lopez.   

Abstract

We describe here a simple, fast, and reliable bioassay method for therapeutic drug monitoring of voriconazole. Fifty-eight clinical and external quality control samples were evaluated with this microbiological assay, and results were compared with those obtained with a previously validated chromatographic method. A good correlation between both assays was observed. This particular microbiological method was demonstrated to be simple and offers enough precision and accuracy to perform voriconazole therapeutic drug monitoring in laboratories without specialized equipment.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23650161      PMCID： PMC3697380          DOI： 10.1128/AAC.00323-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Development and validation of a fast HPLC/photodiode array detection method for the measurement of voriconazole in human serum samples. A reference laboratory experience.

Authors:  Emilio Cendejas-Bueno; Juan L Rodríguez-Tudela; Manuel Cuenca-Estrella; Alicia Gómez-López
Journal:  Enferm Infecc Microbiol Clin       Date:  2012-07-08       Impact factor: 1.731

2.  Comparison of microbiological and UV-spectrophotometric assays for determination of voriconazole in tablets.

Authors:  Andréa I H Adams; Martin Steppe; Pedro E Fröehlich; Ana M Bergold
Journal:  J AOAC Int       Date:  2006 Jul-Aug       Impact factor: 1.913

Review 3.  Pharmacodynamic implications for use of antifungal agents.

Authors:  Russell E Lewis
Journal:  Curr Opin Pharmacol       Date:  2007-07-09       Impact factor: 5.547

4.  A rapid HPLC assay for voriconazole in human plasma.

Authors:  R Gage; D A Stopher
Journal:  J Pharm Biomed Anal       Date:  1998-09       Impact factor: 3.935

5.  Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma.

Authors:  S Perea; G J Pennick; A Modak; A W Fothergill; D A Sutton; D J Sheehan; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

6.  Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.

Authors:  S Trifilio; R Ortiz; G Pennick; A Verma; J Pi; V Stosor; T Zembower; J Mehta
Journal:  Bone Marrow Transplant       Date:  2005-03       Impact factor: 5.483

7.  Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection.

Authors:  Stéphanie Chhun; Elisabeth Rey; Agnes Tran; Olivier Lortholary; Gérard Pons; Vincent Jullien
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-02-01       Impact factor: 3.205

8.  Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.

Authors:  Andres Pascual; Valérie Nieth; Thierry Calandra; Jacques Bille; Saskia Bolay; Laurent A Decosterd; Thierry Buclin; Paul A Majcherczyk; Dominique Sanglard; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

9.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245
View more
  3 in total

1.  Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins.

Authors:  Maria Siopi; Efthymios Neroutsos; Kalliopi Zisaki; Maria Gamaletsou; Maria Pirounaki; Panagiotis Tsirigotis; Nikolaos Sipsas; Aristides Dokoumetzidis; Evgenios Goussetis; Loukia Zerva; Georgia Valsami; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

2.  A New Application of MALDI Biotyper for a Potential Use in Therapeutic Drug Monitoring of Voriconazole.

Authors:  Iker Falces-Romero; Jesús Mingorance; Julio García-Rodríguez; Emilio Cendejas-Bueno
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

3.  Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy.

Authors:  Lalit Saini; Jack T Seki; Deepali Kumar; Eshetu G Atenafu; David Ec Cole; Betty Yl Wong; Andrea Božović; Joseph M Brandwein
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-09       Impact factor: 2.471
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.